Impact of RAS mutation status on early progression in patients with initially unresectable colorectal liver metastases undergoing conversion therapy: a retrospective analysis - Report - MDSpire

Impact of RAS mutation status on early progression in patients with initially unresectable colorectal liver metastases undergoing conversion therapy: a retrospective analysis

  • By

  • Rong Yang

  • Weili Zhang

  • Jin Lan

  • Weihao Li

  • Zhigang Hong

  • Jun Chi

  • Jianhong Peng

  • Cong Li

  • Xiaojun Wu

  • July 1, 2026

  • 0 min

Share

Clinical Report: Influence of RAS Mutation Status on Early Disease Progression

Overview

This study evaluates the prognostic impact of RAS mutation status in patients with initially unresectable colorectal liver metastases (IU-CRLM) undergoing conversion therapy.

Background

Colorectal cancer liver metastases (CRLM) are a significant cause of morbidity and mortality, with many patients initially deemed unresectable. Understanding the factors that contribute to early disease progression is crucial for optimizing treatment strategies. RAS mutations are known to correlate with poor outcomes in CRLM.

Data Highlights

ParameterRAS MutantRAS Wild-TypeP-value
Early Progression/Recurrence Rate41.2%19.6%0.004
Early Progression Rate (Failed Conversion)36.7%13.0%0.012
Early Recurrence Rate (Successful Conversion)47.6%27.3%0.142

Key Findings

  • 44.8% of patients achieved successful conversion from initially unresectable CRLM.
  • 26.3% of patients harbored RAS mutations.
  • RAS-mutant patients had a significantly higher early progression/recurrence rate compared to RAS wild-type patients (41.2% vs. 19.6%, P = 0.004).
  • In patients with failed conversion, RAS mutation was linked to a higher early progression rate (36.7% vs. 13.0%, P = 0.012).
  • RAS mutation status remained an independent predictor of early progression/recurrence in a clinically adjusted model (OR: 3.546, 95% CI: 1.290–9.752, P = 0.014).

Clinical Implications

The findings indicate that RAS mutation status should be considered when evaluating patients with IU-CRLM for conversion therapy.

Conclusion

RAS mutation status is a significant factor influencing early disease progression in patients with IU-CRLM undergoing conversion therapy.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Influence of RAS Mutation Status on Early Disease Progression
  2. Outcomes of Treatment and Predictive Factors in Colorectal Cancer Patients with Concurrent Lung Metastases During the Era of Conversion Therapy
  3. BJS (British Journal of Surgery) — Prognostic Molecular Indicators for Liver Transplantation in Patients with Unresectable Metastatic Colorectal Cancer
  4. The ASCO Post — How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
  5. Outcomes and Influential Factors for Surgical Conversion in Initially Unresectable Advanced Colorectal Cancer
  6. Outcomes of Treatment and Predictive Factors in Colorectal Cancer Patients with Concurrent Lung Metastases During the Era of Conversion Therapy
  7. Prognostic Molecular Indicators for Liver Transplantation in Patients with Unresectable Metastatic Colorectal Cancer
  8. How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
  9. A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases
  10. Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis
  11. 2025 Updated version v1.0 SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022) - PMC
  12. Patterns of recurrence after curative intent hepatic resection for colorectal liver metastasis - PubMed
  13. ASCO 2025: metastatic colorectal cancer—focus on precision oncology | memo - Magazine of European Medical Oncology | Springer Nature Link

Original Source(s)

Impact of RAS mutation status on early progression in patients with initially unresectable colorectal liver metastases undergoing conversion therapy: a retrospective analysis

  • by Rong Yang, Weili Zhang, Jin Lan, Weihao Li, Zhigang Hong, Jun Chi, Jianhong Peng, Cong Li, Xiaojun Wu

  • July 1, 2026

Related Content

Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors

Effectiveness of nurse-led dietary modification recommendations in the management of defecation dysfunction among patients with rectal cancer after sphincter-saving surgery: a scoping review

Endoscopic mucosal resection versus endoscopic submucosal dissection for early colorectal cancer and precursor lesions: a retrospective study